



Vigilancia de la Poliomielitis en las Américas

Cuadro No.1
Análisis de las muestras de heces de casos
Últimas 52 semanas (2004/18-2005/17)

| Lab. | País | Total* | SIN RESULTADOS | | | % Aisla- miento | AISLAMIENTO DE ENTEROVIRUS | | | | |
|-------|------|--------|-------------------|-------------|-------------|--------------------|----------------------------|----------------------|------------|---------|---|
| | | | Aún no en lab. | <28 Días | >28 Días | | Negativo | Otros Enterovirus | Poliovirus | | |
| | | | | | | | | Pendiente | Vacunal | Salvaje | |
| BEL | BRA | 25 | 0 | 0 | 0 | 8,0 | 23 | 1 | 0 | 1 | 0 |
| CAR | BLZ | 1 | 0 | 0 | 0 | 0,0 | 1 | 0 | 0 | 0 | 0 |
| | DOR | 13 | 2 | 0 | 0 | 9,1 | 10 | 1 | 0 | 0 | 0 |
| | GUY | 11 | 0 | 0 | 0 | 9,1 | 10 | 1 | 0 | 0 | 0 |
| | HAI | 7 | 3 | 0 | 0 | 25,0 | 3 | 1 | 0 | 0 | 0 |
| | HON | 60 | 2 | 6 | 0 | 19,2 | 42 | 10 | 0 | 0 | 0 |
| | JAM | 6 | 1 | 0 | 0 | 20,0 | 4 | 1 | 0 | 0 | 0 |
| | STV | 1 | 0 | 0 | 0 | 0,0 | 1 | 0 | 0 | 0 | 0 |
| | SUR | 2 | 1 | 0 | 0 | 100,0 | 0 | 1 | 0 | 0 | 0 |
| TRT | 5 | 0 | 0 | 0 | 0,0 | 5 | 0 | 0 | 0 | 0 | |
| FIO | BRA | 412 | 84 | 1 | 13 | 16,6 | 262 | 40 | 0 | 12 | 0 |
| | PER | 75 | 5 | 2 | 3 | 15,4 | 55 | 9 | 0 | 1 | 0 |
| IEC | BRA | 33 | 6 | 0 | 1 | 3,8 | 25 | 1 | 0 | 0 | 0 |
| INC | ELS | 60 | 0 | 0 | 0 | 20,0 | 48 | 12 | 0 | 0 | 0 |
| | GUT | 96 | 0 | 5 | 2 | 12,4 | 78 | 11 | 0 | 0 | 0 |
| | NIC | 30 | 1 | 0 | 6 | 26,1 | 17 | 6 | 0 | 0 | 0 |
| | PAN | 13 | 0 | 0 | 0 | 15,4 | 11 | 2 | 0 | 0 | 0 |
| INCAP | COR | 6 | 0 | 0 | 0 | 16,7 | 5 | 1 | 0 | 0 | 0 |
| INDRE | MEX | 345 | 0 | 0 | 19 | 16,0 | 274 | 52 | 0 | 0 | 0 |
| INH | VEN | 124 | 0 | 3 | 1 | 10,0 | 108 | 12 | 0 | 0 | 0 |
| INS | COL | 163 | 0 | 7 | 1 | 12,3 | 136 | 19 | 0 | 0 | 0 |
| | ECU | 17 | 0 | 0 | 0 | 11,8 | 15 | 2 | 0 | 0 | 0 |
| ISP | CHI | 53 | 0 | 1 | 1 | 17,6 | 42 | 8 | 0 | 1 | 0 |
| MAL | ARG | 119 | 0 | 7 | 3 | 10,1 | 98 | 4 | 0 | 7 | 0 |
| | BOL | 65 | 8 | 0 | 3 | 22,2 | 42 | 7 | 0 | 5 | 0 |
| | CHI | 26 | 0 | 0 | 0 | 0,0 | 26 | 0 | 0 | 0 | 0 |
| | PAR | 31 | 0 | 0 | 3 | 3,6 | 27 | 1 | 0 | 0 | 0 |
| | URU | 2 | 0 | 0 | 0 | 0,0 | 2 | 0 | 0 | 0 | 0 |
| TOTAL | | 1801 | 113 | 32 | 56 | 14,4 | 1370 | 203 | 0 | 27 | 0 |

* Cada muestra se refiere a un individuo

Muestras de casos solamente

Cuadro No.2
Poliovirus con diferenciación intratípica pendiente
Últimas 52 semanas (2004/18-2005/17)

| LAB | PAIS | POLIOVIRUS | | | | | | | | | | | | TOTAL |
|-------|------|-------------------|----|----|------|-----------------------|----|----|------|-----------------------|----|----|------|-------|
| | | AÚN NO EN EL LAB, | | | | EN LAB < de 4 semanas | | | | EN LAB > de 4 semanas | | | | |
| | | P1 | P2 | P3 | Mez. | P1 | P2 | P3 | Mez. | P1 | P2 | P3 | Mez. | |
| TOTAL | | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |

Muestras de casos solamente

LA POLIOMIELITIS HA SIDO ERRADICADA DE LAS AMÉRICAS

El último caso con poliovirus salvaje fue detectado
el 5 de septiembre de 1991, en Perú

El boletín de vigilancia de la poliomielitis se encuentra en:
<http://www.paho.org/spanish/ad/fch/im/polioyelitis.htm>



Vigilancia de Parálisis Flácida Aguda

Vol. 20, No. 17

Cuadro No.1
Casos de parálisis flácida aguda bajo investigación
según semana de notificación

| PAIS | TOTAL | ACUM. | Semana | | | | | | | | |
|-------|-------|-------|--------|------|-----|-----|------|----|----|----|----|
| | | | 2004 | 2005 | 1-4 | 5-8 | 9-12 | 13 | 14 | 15 | 16 |
| ARG | 5 | 18 | 2 | 2 | 4 | 1 | 1 | 3 | 3 | 2 | |
| BOL | 0 | 11 | 0 | 0 | 3 | 2 | 5 | 1 | 0 | 0 | |
| BRA | 1 | 91 | 10 | 29 | 41 | 10 | 1 | 0 | 0 | 0 | |
| CAN | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| CAR | 0 | 7 | 3 | 1 | 2 | 0 | 0 | 1 | 0 | 0 | |
| CHI | 7 | 9 | 1 | 0 | 6 | 0 | 1 | 1 | 0 | 0 | |
| COL | 0 | 8 | 0 | 0 | 1 | 1 | 4 | 1 | 1 | 0 | |
| COR | 5 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| CUB | 0 | 7 | 1 | 2 | 4 | 0 | 0 | 0 | 0 | 0 | |
| DOR | 1 | 2 | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 0 | |
| ECU | 0 | 2 | 0 | 0 | 2 | 0 | 0 | 0 | 0 | 0 | |
| ELS | 15 | 8 | 1 | 5 | 2 | 0 | 0 | 0 | 0 | 0 | |
| GUT | 1 | 6 | 0 | 0 | 1 | 1 | 0 | 3 | 1 | 0 | |
| HAI | 6 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| HON | 0 | 8 | 0 | 2 | 3 | 1 | 2 | 0 | 0 | 0 | |
| MEX | 0 | 57 | 14 | 25 | 17 | 1 | 0 | 0 | 0 | 0 | |
| NIC | 0 | 7 | 4 | 0 | 2 | 1 | 0 | 0 | 0 | 0 | |
| PAN | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| PAR | 1 | 2 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | |
| PER | 0 | 10 | 1 | 3 | 5 | 0 | 1 | 0 | 0 | 0 | |
| URU | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 0 | |
| USA | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| VEN | 0 | 4 | 1 | 0 | 0 | 1 | 2 | 0 | 0 | 0 | |
| Total | 42 | 260 | 39 | 70 | 94 | 19 | 19 | 12 | 5 | 2 | |

Cuadro No.2
Casos de PFA notificados, tasa por 100,000 <15 años,
% de casos investigados dentro 48 horas, % con 1 muestra
adecuada y % de unidades notificando semanalmente

| PAIS | Total 2004 | | Ultimas 52 semanas (2004/18-2005/17) | | | | |
|--------|------------|------|--------------------------------------|------|--------------------|---------------------|------------------------------|
| | CASOS | TASA | CASOS | TASA | % INV, <48 hrs, | %1 Mues- tra+ | % Sitios notifi- caron |
| ARG | 130 | 1,27 | 125 | 1,22 | 86 | 70 | 70 |
| BOL | 80 | 2,26 | 65 | 1,81 | 94 | 91 | 74 |
| BRA | 636 | 1,23 | 541 | 1,05 | 98 | 75 | 92 |
| CAN | NR | NR | NR | NR | NR | NR | NR |
| CAR | 28 | 1,31 | 27 | 1,26 | 93 | 56 | 98 |
| CHI | 84 | 1,95 | 91 | 2,12 | 90 | 80 | 97 |
| COL | 197 | 1,41 | 163 | 1,16 | 69 | 82 | 93 |
| COR | 8 | 0,65 | 8 | 0,65 | 75 | 88 | 76 |
| CUB | 18 | 0,79 | 18 | 0,83 | 100 | 100 | 100 |
| DOR | 26 | 0,86 | 15 | 0,49 | 87 | 60 | 67 |
| ECU | 22 | 0,51 | 19 | 0,44 | 95 | 79 | 91 |
| ELS | 102 | 4,39 | 83 | 3,55 | 100 | 81 | 76 |
| GUT | 108 | 2,37 | 97 | 2,13 | 87 | 79 | 53 |
| HAI | 17 | 0,53 | 13 | 0,32 | 69 | 38 | 0 |
| HON | 65 | 2,32 | 60 | 2,08 | 95 | 97 | 91 |
| MEX | 464 | 1,42 | 392 | 1,20 | 97 | 77 | 94 |
| NIC | 30 | 1,29 | 31 | 1,45 | 100 | 100 | 100 |
| PAN | 13 | 1,34 | 13 | 1,33 | 100 | 92 | 91 |
| PAR | 35 | 1,67 | 31 | 1,48 | 87 | 77 | 91 |
| PER | 92 | 1,02 | 76 | 0,84 | 93 | 89 | 0 |
| URU | 4 | 0,49 | 4 | 0,49 | 100 | 50 | 54 |
| USA | NR | NR | NR | NR | NR | NR | NR |
| VEN | 133 | 1,61 | 125 | 1,51 | 87 | 88 | 84 |
| Total§ | 2292 | 1,38 | 1997 | 1,20 | 92 | 79 | 92 |

+ Tomado dentro de los primeros 14 días del inicio de parálisis
§ Excluyendo Canadá y EUA
NR - No reportes

Cuadro No.3
Casos confirmados de poliomieltis
por semana de inicio

Hasta la semana 17

| PAIS | TOTAL 2004 | Acumulado | |
|-------|---------------|-----------|------|
| | | 2004 | 2005 |
| ARG | 0 | 0 | 0 |
| BOL | 0 | 0 | 0 |
| BRA | 0 | 0 | 0 |
| CAN | 0 | 0 | 0 |
| CAR | 0 | 0 | 0 |
| CHI | 0 | 0 | 0 |
| COL | 0 | 0 | 0 |
| COR | 0 | 0 | 0 |
| CUB | 0 | 0 | 0 |
| DOR | 0 | 0 | 0 |
| ECU | 0 | 0 | 0 |
| ELS | 0 | 0 | 0 |
| GUT | 0 | 0 | 0 |
| HAI | 0 | 0 | 0 |
| HON | 0 | 0 | 0 |
| MEX | 0 | 0 | 0 |
| NIC | 0 | 0 | 0 |
| PAN | 0 | 0 | 0 |
| PAR | 0 | 0 | 0 |
| PER | 0 | 0 | 0 |
| URU | 0 | 0 | 0 |
| USA | 0 | 0 | 0 |
| VEN | 0 | 0 | 0 |
| Total | 0 | 0 | 0 |

CAR incluye informes de todos sus
Países Miembros

Cuadro No.4
Casos compatibles de poliomieltis
por semana de inicio

Hasta la semana 17

| PAIS | TOTAL 2004 | Acumulado | |
|-------|---------------|-----------|------|
| | | 2004 | 2005 |
| ARG | 0 | 0 | 0 |
| BOL | 0 | 0 | 0 |
| BRA | 7 | 0 | 0 |
| CAN | 0 | 0 | 0 |
| CAR | 0 | 0 | 0 |
| CHI | 0 | 0 | 0 |
| COL | 0 | 0 | 0 |
| COR | 0 | 0 | 0 |
| CUB | 0 | 0 | 0 |
| DOR | 0 | 0 | 0 |
| ECU | 0 | 0 | 0 |
| ELS | 0 | 0 | 0 |
| GUT | 1 | 0 | 0 |
| HAI | 4 | 0 | 0 |
| HON | 0 | 0 | 0 |
| MEX | 0 | 0 | 0 |
| NIC | 0 | 0 | 0 |
| PAN | 0 | 0 | 0 |
| PAR | 0 | 0 | 0 |
| PER | 0 | 0 | 0 |
| URU | 0 | 0 | 0 |
| USA | 0 | 0 | 0 |
| VEN | 0 | 0 | 0 |
| Total | 12 | 0 | 0 |

CAR incluye informes de todos sus
Países Miembros